TY - JOUR
T1 - Characteristics and prognosis of interstitial pneumonias complicated with pneumomediastinum
AU - Minomo, Shojiro
AU - Arai, Toru
AU - Higo, Hisao
AU - Tsuji, Taisuke
AU - Tachibana, Kazunobu
AU - Akira, Masanori
AU - Inoue, Yoshikazu
N1 - Funding Information:
The authors thank Takehiko Kobayashi, Toshiya Maekura, Shoko Sonobe, and Yohei Kimura for data management and clinical opinions. This study was partially supported by the Practical Project for Rare Intractable Diseases from Japan Agency for Medical Research and Development ( DLD/14526278 to YI and PAP/14526182 to YI and TA), a grant from the Diffuse Lung Diseases Research Group of the Ministry of Health, Labour and Welfare (H26-Itaku (Nan)-Ippan-077 to YI and TA, and Dif-fuse Lung Disease to YI) and a grant from the National Hospital Organization, Japan (H26–NHO (Kokyu)-01 to YI and TA).
Funding Information:
Yoshikazu Inoue serves as a member of steering committee and advisory board of Boehringer Ingelheim and received research funding from Japan Agency for Medical Research and Development; Toru Arai received honoraria from Boehringer Ingelheim; Shojiro Minomo, Hisao Higo, Taisuke Tsuji, Kazunobu Tachibana and Masanori Akira have no conflict of interest.The authors thank Takehiko Kobayashi, Toshiya Maekura, Shoko Sonobe, and Yohei Kimura for data management and clinical opinions. This study was partially supported by the Practical Project for Rare Intractable Diseases from Japan Agency for Medical Research and Development (DLD/14526278 to YI and PAP/14526182 to YI and TA), a grant from the Diffuse Lung Diseases Research Group of the Ministry of Health, Labour and Welfare (H26-Itaku (Nan)-Ippan-077 to YI and TA, and Dif-fuse Lung Disease to YI) and a grant from the National Hospital Organization, Japan (H26–NHO (Kokyu)-01 to YI and TA).
Publisher Copyright:
© 2020 The Japanese Respiratory Society
PY - 2020/7
Y1 - 2020/7
N2 - Background: The clinical characteristics and prognostic impact of complication with pneumomediastinum in patients with interstitial pneumonias (IPs) are not well studied due to the relatively limited nature of available reports. The purpose of this study was to clarify the characteristics and prognostic factors of IPs complicated with pneumomediastinum. Methods: Consecutive patients with IPs complicated with pneumomediastinum detected by computed tomography (CT) between July 1, 2011, and April 30, 2014 were retrospectively reviewed. Clinical data including symptoms associated with pneumomediastinum, laboratory data, lung function tests, treatments, and mortality were collected from medical records. Results: Forty-five patients (25 males, 20 females), including 32 with idiopathic IP (IIPs) and 13 connective tissue disease-associated interstitial lung diseases (CTD-ILDs) were identified. The median age of onset of pneumomediastinum was 72 years (interquartile range [IQR] 68–79 years). The most common symptom associated with occurrence of pneumomediastinum was appearance or worsening of dyspnoea. No specific treatment was performed for most (84%) of the cases. The median period between occurrence and improvement of pneumomediastinum was 29 days (IQR 5–69 days). Multivariate analysis revealed that IIPs and no improvement of pneumomediastinum were associated with poor prognosis. Conclusions: Patients with IIPs complicated with pneumomediastinum and those without improvement of pneumomediastinum had poor prognosis.
AB - Background: The clinical characteristics and prognostic impact of complication with pneumomediastinum in patients with interstitial pneumonias (IPs) are not well studied due to the relatively limited nature of available reports. The purpose of this study was to clarify the characteristics and prognostic factors of IPs complicated with pneumomediastinum. Methods: Consecutive patients with IPs complicated with pneumomediastinum detected by computed tomography (CT) between July 1, 2011, and April 30, 2014 were retrospectively reviewed. Clinical data including symptoms associated with pneumomediastinum, laboratory data, lung function tests, treatments, and mortality were collected from medical records. Results: Forty-five patients (25 males, 20 females), including 32 with idiopathic IP (IIPs) and 13 connective tissue disease-associated interstitial lung diseases (CTD-ILDs) were identified. The median age of onset of pneumomediastinum was 72 years (interquartile range [IQR] 68–79 years). The most common symptom associated with occurrence of pneumomediastinum was appearance or worsening of dyspnoea. No specific treatment was performed for most (84%) of the cases. The median period between occurrence and improvement of pneumomediastinum was 29 days (IQR 5–69 days). Multivariate analysis revealed that IIPs and no improvement of pneumomediastinum were associated with poor prognosis. Conclusions: Patients with IIPs complicated with pneumomediastinum and those without improvement of pneumomediastinum had poor prognosis.
KW - Connective tissue disease-associated interstitial lung diseases
KW - Idiopathic interstitial pneumonias
KW - Pneumomediastinum
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=85083008965&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083008965&partnerID=8YFLogxK
U2 - 10.1016/j.resinv.2020.02.007
DO - 10.1016/j.resinv.2020.02.007
M3 - Article
C2 - 32278605
AN - SCOPUS:85083008965
SN - 2212-5345
VL - 58
SP - 262
EP - 268
JO - Respiratory Investigation
JF - Respiratory Investigation
IS - 4
ER -